Coherus Biosciences Inc v. AbbVie Biotechnology Ltd

Dorothy P. Whelan

Michael J. Kane

Louis Fogel

Charles E. Lipsey

Steven O'Connor

John M. Williamson

Scott E. Kamholz

William B. Raich

Prosecution History analysis

Examiner Search analysis

Invalidity Framework analysis

Rheumatoid arthritis dosing patent challenged: van de Putte & Kempeni prior art argues biweekly adalimumab administration was obvious for all 4 claims.

Abbvie Biotechnology Ltd

Abbvie Co

Coherus Biosciences Inc

Last Docket Entry Date

Total Docket Entries

Patent Trial and Appeal Board

IPR2016-00188 | Coherus Biosciences Inc v. AbbVie Biotechnology Ltd | Ex Parte

Judge	Cases	Inst. Rate	FWD Inv. Rate
Erica A Franklin	400+	56%	70%
James T Moore	100+	56%	82%
Michelle N Ankenbrand	200+	50%	81%
Toni R Scheiner	200+	52%	86%

Name	Ratings
Fish & Richardson	L5 E
Dorothy P. Whelan	L5 E
Michael J. Kane	-- -- --
Jenner & Block LLP	L1 C
Louis Fogel	-- -- --

Name	Ratings
Abbvie Biotechnology Ltd	L4 D
Abbvie Co	L4 D

Name	Ratings
Finnegan Henderson Farabow Garrett & Dunner LLP	L5 B
Steven O'Connor	L2 E
Charles E. Lipsey	-- -- --
John M. Williamson	-- -- --
William B. Raich	-- -- --
Foley Hoag LLP	L1 D
Scott E. Kamholz	-- -- --